Short CommunicationARVANIL (cas 128007-31-8), a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
-
Add time:08/25/2019 Source:sciencedirect.com
The present study was designed to examine whether arvanil (N-arachidonoyl-vanillyl-amide), an endocannabinoid/vanilloid structural “hybrid”, might provide symptom relief in the rat model of Huntington's disease (HD) generated by bilateral intrastriatal application of 3-nitropropionic acid (3-NP), where previous evidence suggests that hybrid cannabinoid/vanilloid compounds might be effective. As expected, arvanil did reduce ambulation, stereotypic activity, and number of hole entries, and increased the inactivity, in control rats. It was also active in 3-NP-lesioned rats, where, despite its lowering effects on stereotypic activity and number of hole entries, arvanil reduced the hyperkinesia (increased ambulation) typical of these rats, and also increased the inactivity, these two effects being more moderate than those found in control rats. Arvanil caused its antihyperkinetic effects in 3-NP-lesioned rats presumably by enhancing excitatory transmission at the globus pallidus, since it increased glutamate content in this region. This contrasts with its effects in control rats where arvanil enhanced GABA transmission at the globus pallidus. In summary, arvanil does alleviate hyperkinesia typical of HD, although it also affects locomotion in normal rats. Nevertheless, considering the lack of efficacious pharmacological treatments in this basal ganglia disorder, our findings might provide the basis for the development of more specific drugs against HD.
We also recommend Trading Suppliers and Manufacturers of ARVANIL (cas 128007-31-8). Pls Click Website Link as below: cas 128007-31-8 suppliers
Prev:ARVANIL (cas 128007-31-8) inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis
Next:ARVANIL (cas 128007-31-8) and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The Synthesis of N-Vanillyl-arachidonoyl-amide (ARVANIL (cas 128007-31-8)) and its Analogs: An Improved Procedure for the Synthesis of the Key Synthon Methyl 14-Hydroxy-(all-cis)-5,8,11-tetradecatrienoate08/29/2019
- ARVANIL (cas 128007-31-8)-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors08/28/2019
- Effect of ARVANIL (cas 128007-31-8) (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide–capsaicin hybrid, on ion currents in NG108-15 neuronal cells08/27/2019
- ARVANIL (cas 128007-31-8) and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells08/26/2019
- ARVANIL (cas 128007-31-8) inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis08/24/2019
- Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to ARVANIL (cas 128007-31-8), an endocannabinoid and vanilloid hybrid, in rats08/23/2019
- Pulmonary, Gastrointestinal and Urogenital PharmacologyMidcervical vagotomy precludes respiratory response to novel anti-inflammatory and anti-tumour drug ARVANIL (cas 128007-31-8) in rats08/22/2019
- Short communicationARVANIL (cas 128007-31-8), olvanil, AM 1172 and LY 2183240 (various cannabinoid CB1 receptor agonists) increase the threshold for maximal electroshock-induced seizures in mice08/21/2019
